SAN FRANCISCO – Shares of Pharmacyclics Inc. jumped 11.4 percent in afterhours trading Monday following a lively afternoon presentation during which the Sunnyvale, Calif.-based firm told attendees of the J.P. Morgan Healthcare Conference that it expected cancer drug Imbruvica (ibrutinib) to hit blockbuster status in 2015.